EU backs drug for rare sun intolerance from Australia’s Clinuvel

LONDON (Reuters) – European patients with a rare genetic disease that causes intolerance to sunlight should soon have a new treatment option, following a green light for a drug from Australia’s Clinuvel Pharmaceuticals. The biotech company is pinning its hopes on Scenesse, the first medicine for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP). After exposure to sunlight, patients with EPP feel a stinging pain in sun-exposed skin and prolonged exposure can lead to an incapacitating pain, often followed by redness and swelling. …
Medications/Drugs News Headlines – Yahoo! News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us